Opposition chief blames Kerala govt for generic SMA drug mishandling

Opposition leader Pinarayi Vijayan accused the Kerala government of lapses and lack of transparency in the distribution of the generic SMA drug Risdiplam at SAT Hospital. He said the government ignored a letter from parents of children with spinal muscular atrophy that raised concerns over the sudden change of medicine. Vijayan claimed the Health Minister tried to paint the criticism as an attack on generic drugs, while the real issue is the failure to follow proper safeguards in drug purchase. He noted that the new administration approved the generic drug in July 2026, despite SAT Hospital officials stating the decision to buy Natco’s generic had been finalised in February 2026 under the previous Left government. Vijayan questioned whether the required procedures were observed and reiterated allegations that “clinical trial drugs” were handed to children, warning that such actions heighten parental anxiety. He demanded a full explanation of how trial‑stage medicines entered the public supply and why parents were not informed. The leader urged the government to disclose all facts, insisting that children must not be turned into subjects of experimentation.

Context

SMA is a rare genetic disorder that weakens muscles; Risdiplam is an approved treatment whose high cost can be reduced by generic versions. Transparent procurement and clear communication are essential to maintain public trust in health programmes.